Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Comparing biomarkers as principal surrogate endpoints.

Huang Y, Gilbert PB.

Biometrics. 2011 Dec;67(4):1442-51. doi: 10.1111/j.1541-0420.2011.01603.x. Epub 2011 Apr 22.

3.

Statistical considerations for the next generation of clinical trials.

Wu W, Shi Q, Sargent DJ.

Semin Oncol. 2011 Aug;38(4):598-604. doi: 10.1053/j.seminoncol.2011.05.014. Review.

PMID:
21810519
4.

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.

Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, Phillips A, Chêne G, Babiker A, Thiébaut R; NEAT-WP4.

Clin Trials. 2010 Feb;7(1):19-35. doi: 10.1177/1740774509356117. Review.

PMID:
20156955
5.

Statistical evaluation of biomarkers as surrogate endpoints: a literature review.

Weir CJ, Walley RJ.

Stat Med. 2006 Jan 30;25(2):183-203. Review.

PMID:
16252272
6.

Surrogate endpoints in randomized cardiovascular clinical trials.

Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F.

Fundam Clin Pharmacol. 2011 Aug;25(4):411-3. doi: 10.1111/j.1472-8206.2010.00865.x. Epub 2010 Aug 4. Review.

PMID:
20698890
7.

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.

Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO 3rd, Hughes M, Altman D, Buyse M, Galbraith S, Wells G.

J Rheumatol. 2007 Mar;34(3):607-15.

PMID:
17343307
8.

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011.

Bikdeli B, Punnanithinont N, Akram Y, Lee I, Desai NR, Ross JS, Krumholz HM.

J Am Heart Assoc. 2017 Mar 21;6(3). pii: e005285. doi: 10.1161/JAHA.116.005285. Review.

9.

Biomarkers and surrogate endpoints in glaucoma clinical trials.

Medeiros FA.

Br J Ophthalmol. 2015 May;99(5):599-603. doi: 10.1136/bjophthalmol-2014-305550. Epub 2014 Jul 17. Review.

10.
11.

Endpoints in respiratory diseases.

de Benedictis FM, Guidi R, Carraro S, Baraldi E; TEDDY European Network of Excellence.

Eur J Clin Pharmacol. 2011 May;67 Suppl 1:49-59. doi: 10.1007/s00228-010-0922-2. Epub 2010 Nov 23. Review.

PMID:
21104409
12.

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma.

Medeiros FA.

Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO20-BIO26. doi: 10.1167/iovs.17-21987. Review.

14.

Novel procedures for validating surrogate endpoints in clinical trials.

Cleophas TJ, Zwinderman AH, Chaib AH.

Curr Clin Pharmacol. 2007 May;2(2):123-8. Review.

PMID:
18690859
15.

Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials.

Patel RB, Vaduganathan M, Samman-Tahhan A, Kalogeropoulos AP, Georgiopoulou VV, Fonarow GC, Gheorghiade M, Butler J.

Am J Cardiol. 2016 Jun 1;117(11):1845-50. doi: 10.1016/j.amjcard.2016.03.021. Epub 2016 Mar 19. Review.

PMID:
27085935
16.

[Immunological surrogate endpoints to evaluate vaccine efficacy].

Jin P, Li J, Zhou Y, Zhu F.

Zhonghua Yu Fang Yi Xue Za Zhi. 2015 Dec;49(12):1110-4. Review. Chinese.

PMID:
26887309
17.

Biomarkers and Surrogate Endpoints in Drug Development: A European Regulatory View.

Wickström K, Moseley J.

Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO27-BIO33. doi: 10.1167/iovs.17-21778. Review.

PMID:
28475700
18.

Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.

Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T.

Biom J. 2016 Jan;58(1):104-32. doi: 10.1002/bimj.201400049. Epub 2015 Feb 12. Review.

PMID:
25682941
19.

Decade-Long Profile of Imaging Biomarker Use in Ophthalmic Clinical Trials.

Villani E, Massaro D, Scaramuzzi M, Hamrah P, Medeiros FA, Nucci P.

Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO76-BIO81. doi: 10.1167/iovs.17-21790. Review.

20.

Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review.

Ensor H, Lee RJ, Sudlow C, Weir CJ.

J Biopharm Stat. 2016;26(5):859-79. doi: 10.1080/10543406.2015.1094811. Epub 2015 Sep 21. Review.

PMID:
26391022

Supplemental Content

Support Center